Compare Cytokinetics Inc (CYTK) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Simon Property Group Inc — how do they compare? Cytokinetics Inc trades at $76.3 (market cap $10.63B), while Simon Property Group Inc trades at $220.26 (market cap $71.03B). The key difference: Simon Property Group Inc is far larger — about 6.7× Cytokinetics Inc's market cap, and Simon Property Group Inc pays a 4.05% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SPG | |
|---|---|---|
Market Cap | $10.63B | $71.03B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $236.70 |
52-Week Low | $34.31 | $169.22 |
Enterprise Value | $10.74B | $99.48B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.
The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.
Simon Property Group (SPG) trades at $220.37, down 0.08% on the day, with a bearish technical signal but strong fundamentals. Recent Q2 2026 earnings showed an EPS miss ($1.49 actual vs. $1.64 expected), though FFO beat estimates and full-year guidance was raised. The company maintains robust profitability with a net income margin of 66.57% and pays consistent dividends.
Outlook is mixed: solid operational performance and raised guidance support upside near the $226.58 consensus price target, but high debt ($24.21B) and economic sensitivity pose risks. Analyst sentiment leans neutral with 54.05% hold ratings, reflecting cautious optimism amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
